Recap: Osmotica Pharmaceuticals Q2 Earnings

Shares of Osmotica Pharmaceuticals OSMT decreased 4.46% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share fell 650.00% year over year to ($0.22), which missed the estimate of ($0.12).

Revenue of $37,532,000 declined by 34.76% from the same period last year, which missed the estimate of $40,830,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Osmotica Pharmaceuticals hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 11, 2020

Time: 04:30 PM

ET Webcast URL: https://ir.osmotica.com/events-presentations

Technicals

Company's 52-week high was at $9.67

52-week low: $2.70

Price action over last quarter: Up 39.90%

Company Overview

Osmotica Pharmaceuticals PLC is a fully-integrated biopharmaceutical company. It is focused on developing, manufacturing and commercializing specialty products. The product portfolio of the group includes specialty neurology and women's health products, which are primarily complex formulations of generic drugs. Osmotica has a late?stage development pipeline by two NDA candidates that recently completed Phase III clinical trials: arbaclofen ER for spasticity in multiple sclerosis patients and RVL?1201 for the treatment of acquired blepharoptosis, or droopy eyelid.